936498-64-5
Chemical Structure
ICL-CCIC-0019
- CAS No.: 936498-64-5
- Formula:C26H44Br2N4
- Molecular Weight:572.46
IUPAC Name: 1,1'-(dodecane-1,12-diyl)bis(4-(dimethylamino)pyridin-1-ium) bromide
InChIKey: SRYRXSJEWKGQSC-UHFFFAOYSA-L
SMILES: CN(C)C1=CC=[N+](C=C1)CCCCCCCCCCCC[N+]2=CC=C(C=C2)N(C)C.[Br-].[Br-]
Biological Activity: ICL-CCIC-0019 is a CHKA inhibitor with a human IC50 of 270 nM. ICL-CCIC-0019 blocks choline phosphorylation and phosphatidylcholine synthesis via the CDP-choline pathway. ICL-CCIC-0019 inhibits choline uptake, mitochondrial respiration, TCA cycle flux, de novo fatty acid synthesis, and mitochondrial membrane potential, while inducing G1 phase arrest, ER stress, caspase-dependent apoptosis, AMPK activation, glycolysis, acetate uptake, and mitochondrial network disruption. ICL-CCIC-0019 can be used for cancer research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ICL-CCIC-0019 | 97.80% | ICL-CCIC-0019 is a CHKA inhibitor with a human IC50 of 270 nM. ICL-CCIC-0019 blocks choline phosphorylation and phosphatidylcholine synthesis via the CDP-choline pathway. ICL-CCIC-0019 inhibits choline uptake, mitochondrial respiration, TCA cycle flux, de novo fatty acid synthesis, and mitochondrial membrane potential, while inducing G1 phase arrest, ER stress, caspase-dependent apoptosis, AMPK activation, glycolysis, acetate uptake, and mitochondrial network disruption. ICL-CCIC-0019 can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang N, et al. Novel Non-Congeneric Derivatives of the Choline Kinase Alpha Inhibitor ICL-CCIC-0019. Pharmaceutics. 2021 Jul 14;13(7):1078.
- [2]. Trousil S, et al. The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth. Oncotarget. 2016 Jun 14;7(24):37103-37120. [Content Brief]
